Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 106
interventional 74
Observational 26
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 28
Drug|placebo 25
Other 8
Behavioral 3
Drug|Other 3
Procedure 2
Biological 1
Dietary Supplement 1
Dietary Supplement|Other 1
Dietary Supplement|placebo 1
Drug|Other|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 33
Denmark 6
Italy 4
Japan 4
France 3
NA 3
Austria 2
Australia|Belgium|United States|Argentina|Canada|France|Germany|Italy|Netherlands|Poland|Romania|Russian Federation|United Kingdom 1
Austria|France|Germany 1
Belgium|Germany|Italy|United Kingdom 1
Belgium|Netherlands 1
Belgium|United States|Argentina|Australia|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|Norway|Poland|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
Canada 1
China 1
Iran, Islamic Republic of 1
Korea, Republic of 1
Netherlands 1
Netherlands|Spain 1
Switzerland 1
Turkey 1
United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|Czechia|Denmark|Germany|Hungary|Israel|Italy|Netherlands|Norway|Poland|Romania|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|China|Czechia|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Portugal|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Czechia|France|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Canada|Czech Republic|Hungary|Italy|Korea, Republic of|Lithuania|Moldova, Republic of|Poland|Romania|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Japan|Argentina|Australia|Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Poland|Romania|Russian Federation|United Kingdom 1

Sites per Study

Site_count Study_Count
1 45
2 3
3 1
5 1
6 3
7 3
11 2
13 1
18 1
20 2
24 1
25 1
30 1
31 1
35 1
67 1
78 1
87 1
99 1
133 1
210 1
231 1

Phase

Phase Study_Count
Phase 2 21
Phase 3 19
N/A 16
Phase 2/Phase 3 6
Phase 4 5
Phase 1 4
Phase 1/Phase 2 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 17
2 43
3 8
4 3
5 1
7 1
NA 1

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 14 8.000 6.00 30 1.00000 34.0000 3.0000 68.0
1st Qu. 14 17.250 9.00 41 20.00000 35.0000 73.0000 90.0
Median 14 30.500 17.00 52 31.00000 36.5000 110.0000 100.0
Mean 14 126.625 28.75 52 50.71429 137.3333 420.1579 177.8
3rd Qu. 14 49.500 36.75 63 50.00000 41.0000 522.0000 200.0
Max. 14 1450.000 75.00 74 178.00000 640.0000 1803.0000 431.0

Trial Group Type

group_type Group_Count
Experimental 80
Placebo Comparator 31
Active Comparator 22
Other 10
No Intervention 8
NA 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 40
Single Group Assignment 19
Crossover Assignment 10
Sequential Assignment 3
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 60
Basic Science 5
Diagnostic 3
Other 2
Prevention 2
NA 2

Observational Studies

Studies by Country

Country Study_Count
United States 13
France 4
Japan 3
NA 2
Austria|Belgium|France|Germany|Spain|Switzerland|United Kingdom 1
Canada 1
Korea, Republic of 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Czech Republic|France|Germany|Italy|Japan|Netherlands|Norway|Poland|Romania|Spain|Sweden|Switzerland|Turkey|United Kingdom 1

Sites per Study

Site_count Study_Count
1 21
2 1
5 1
19 1
26 1
266 1

Enrollment Metrics

Measure Observational
Min 4.000
1st Qu 36.250
Median 100.000
Mean 1748.923
3rd Qu 380.250
Max 20000.000

Observation Model

observational_model Study_Count
Cohort 16
Case-Control 4
Family-Based 2
Other 2
Case-Only 1
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 14
Retrospective 5
Cross-Sectional 4
Other 3

Registries

Studies by Country

Country Study_Count
United States 5
Germany 1

Sites per Study

Site_count Study_Count
1 4
3 1
12 1

Enrollment Metrics

Measure Registries
Min 100.0
1st Qu 212.5
Median 375.0
Mean 779.0
3rd Qu 593.0
Max 3000.0

Registry Model

observational_model Study_Count
Cohort 4
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 5
Other 1

Follow-up

target_duration Study_Count
10 Years 3
5 Years 1
8 Years 1
84 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03366337 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX https://ClinicalTrials.gov/show/NCT03366337 Completed Reata Pharmaceuticals, Inc. 2019-01-02
NCT03342742 Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03342742 Active, not recruiting University of Colorado, Denver 2020-09-01
NCT03273413 Statin Therapy in Patients With Early Stage ADPKD https://ClinicalTrials.gov/show/NCT03273413 Recruiting University of Colorado, Denver 2021-12-31
NCT03203642 Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD https://ClinicalTrials.gov/show/NCT03203642 Active, not recruiting Kadmon Corporation, LLC 2022-01-31
NCT03102632 A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03102632 Recruiting The Rogosin Institute 2021-12-31
NCT03096080 A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) https://ClinicalTrials.gov/show/NCT03096080 Completed Kadmon Corporation, LLC 2019-09-30
NCT02948179 Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial https://ClinicalTrials.gov/show/NCT02948179 Recruiting Shanghai Changzheng Hospital 2020-09-30
NCT02933268 High Water Intake in Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02933268 Completed Cambridge University Hospitals NHS Foundation Trust 2018-03-31
NCT02903511 Feasibility Study of Metformin Therapy in ADPKD https://ClinicalTrials.gov/show/NCT02903511 Active, not recruiting University of Colorado, Denver 2020-10-31
NCT02776241 Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02776241 Completed Rigshospitalet, Denmark 2017-01-31
NCT02729662 Efficacy of Tolvaptan on ADPKD Patients https://ClinicalTrials.gov/show/NCT02729662 Active, not recruiting Kyorin University 2020-08-31
NCT02697617 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02697617 Active, not recruiting Indiana University 2019-10-31
NCT02558595 Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) https://ClinicalTrials.gov/show/NCT02558595 Completed University of Kansas Medical Center 2017-12-18
NCT02527863 Effect of the Aquaretic Tolvaptan on Nitric Oxide System https://ClinicalTrials.gov/show/NCT02527863 Completed Regional Hospital Holstebro 2016-08-31
NCT02494141 Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD https://ClinicalTrials.gov/show/NCT02494141 Active, not recruiting University of Colorado, Denver 2020-12-31
NCT02251275 Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02251275 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2018-11-09
NCT02225860 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02225860 Completed Tufts Medical Center 2016-02-29
NCT02166489 Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02166489 Completed Royan Institute 2015-12-31
NCT02160145 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02160145 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2017-04-18
NCT02140814 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02140814 Completed University of Kansas Medical Center 2016-02-29
NCT02134899 The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients https://ClinicalTrials.gov/show/NCT02134899 Completed Assistance Publique - Hôpitaux de Paris 2017-11-11
NCT02127437 Lanreotide In Polycystic Kidney Disease Study https://ClinicalTrials.gov/show/NCT02127437 Completed Assistance Publique - Hôpitaux de Paris 2019-07-31
NCT02119052 Effects of Somatostatin on Liver in ADPKD https://ClinicalTrials.gov/show/NCT02119052 Completed Federico II University 2013-09-30
NCT02119013 Effects of Somatostatin on ADPKD Heart https://ClinicalTrials.gov/show/NCT02119013 Completed Federico II University 2013-09-30
NCT02112136 Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD https://ClinicalTrials.gov/show/NCT02112136 Recruiting University Hospital, Brest 2020-12-12
NCT01280721 A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] https://ClinicalTrials.gov/show/NCT01280721 Completed Otsuka Pharmaceutical Co., Ltd. 2014-08-31
NCT02055079 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02055079 Recruiting Medical University of Vienna 2019-04-30
NCT01885559 HALT Progression of Polycystic Kidney Disease Study B https://ClinicalTrials.gov/show/NCT01885559 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2014-06-30
NCT01853553 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT01853553 Completed University of Colorado, Denver 2017-01-31
NCT01810614 A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD) https://ClinicalTrials.gov/show/NCT01810614 Completed University of Kansas Medical Center 2014-11-30
NCT01670110 Pasireotide LAR in Severe Polycystic Liver Disease https://ClinicalTrials.gov/show/NCT01670110 Completed Mayo Clinic 2018-09-30
NCT01632605 The Vienna RAP Pilot Study https://ClinicalTrials.gov/show/NCT01632605 Completed Medical University of Vienna 2012-04-30
NCT01559363 A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD https://ClinicalTrials.gov/show/NCT01559363 Completed Kadmon Corporation, LLC 2019-02-08
NCT01451827 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT01451827 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2013-07-31
NCT01377246 Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency https://ClinicalTrials.gov/show/NCT01377246 Completed Mario Negri Institute for Pharmacological Research 2017-10-18
NCT01336972 Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT01336972 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2011-11-30
NCT04363554 The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT04363554 Completed Regional Hospital Holstebro 2020-04-20
NCT04284657 Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT04284657 Recruiting University of Southern California 2020-12-31
NCT03949894 Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03949894 Recruiting Korea Otsuka Pharmaceutical Co., Ltd. 2022-06-30
NCT03918447 A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON https://ClinicalTrials.gov/show/NCT03918447 Recruiting Reata Pharmaceuticals, Inc. 2023-03-31
NCT03858439 Dietary Intervention in ADPKD on Tolvaptan https://ClinicalTrials.gov/show/NCT03858439 Recruiting McMaster University 2020-09-30
NCT03803124 Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD https://ClinicalTrials.gov/show/NCT03803124 Completed Regional Hospital Holstebro 2017-12-15
NCT03687554 Effect of Venglustat in Patients With Renal Impairment https://ClinicalTrials.gov/show/NCT03687554 Completed Sanofi 2019-02-27
NCT03596957 Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03596957 Recruiting Nordsjaellands Hospital 2019-06-30
NCT03541447 Tolvaptan-Octreotide LAR Combination in ADPKD https://ClinicalTrials.gov/show/NCT03541447 Recruiting Mario Negri Institute for Pharmacological Research 2020-09-30
NCT03487913 The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03487913 Completed Palladio Biosciences 2019-12-02
NCT02656017 Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02656017 Active, not recruiting University of Pittsburgh 2020-12-30
NCT03423810 Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients https://ClinicalTrials.gov/show/NCT03423810 Completed University of Kansas Medical Center 2020-01-30
NCT01233869 Bosutinib For Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT01233869 Completed Pfizer 2014-07-31
NCT01214421 Open-Label Tolvaptan Study in Subjects With ADPKD https://ClinicalTrials.gov/show/NCT01214421 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2016-02-29
NCT01210560 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD https://ClinicalTrials.gov/show/NCT01210560 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2011-06-30
NCT01022424 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] https://ClinicalTrials.gov/show/NCT01022424 Completed Otsuka Pharmaceutical Co., Ltd. 2014-07-31
NCT00841568 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] https://ClinicalTrials.gov/show/NCT00841568 Completed Otsuka Pharmaceutical Co., Ltd. 2010-11-30
NCT03717181 Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT03717181 Enrolling by invitation Palladio Biosciences 2020-12-31
NCT02021110 Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease https://ClinicalTrials.gov/show/NCT02021110 Completed Radboud University 2015-10-31
NCT03523728 A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients https://ClinicalTrials.gov/show/NCT03523728 Recruiting Sanofi 2023-10-31
NCT02964273 Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) https://ClinicalTrials.gov/show/NCT02964273 Active, not recruiting Otsuka Pharmaceutical Development & Commercialization, Inc. 2019-12-02
NCT00784030 High Water Intake to Slow Progression of Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT00784030 Completed NYU Langone Health 2009-05-31
NCT00759369 Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00759369 Completed University of Kansas Medical Center 2009-07-31
NCT00598377 Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT00598377 Completed Istanbul University 2007-09-30
NCT00571909 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study https://ClinicalTrials.gov/show/NCT00571909 Completed Mayo Clinic 2016-01-31
NCT00565097 Lanreotide as Treatment of Polycystic Livers https://ClinicalTrials.gov/show/NCT00565097 Completed Radboud University NA
NCT00491517 Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety https://ClinicalTrials.gov/show/NCT00491517 Completed Mario Negri Institute for Pharmacological Research 2009-07-31
NCT00456365 Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00456365 Completed University of Colorado, Denver 2012-10-31
NCT00428948 Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00428948 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2012-01-31
NCT00426153 Octreotide in Severe Polycystic Liver Disease https://ClinicalTrials.gov/show/NCT00426153 Completed Mayo Clinic 2008-10-31
NCT00414440 Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT00414440 Completed Novartis 2013-10-31
NCT00413777 Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00413777 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2010-06-30
NCT00410007 The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT00410007 Completed Regional Hospital Holstebro 2010-10-31
NCT00346918 Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00346918 Completed University of Zurich 2010-01-31
NCT00345137 Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis https://ClinicalTrials.gov/show/NCT00345137 Completed Regional Hospital Holstebro NA
NCT00309283 Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study https://ClinicalTrials.gov/show/NCT00309283 Completed Mario Negri Institute for Pharmacological Research 2012-01-31
NCT00286156 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT00286156 Completed The Cleveland Clinic 2012-03-31
NCT00283686 HALT Progression of Polycystic Kidney Disease Study A https://ClinicalTrials.gov/show/NCT00283686 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2014-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02925221 Canadian Medical Assessment of JINARCâ„¢ Outcomes Registry https://ClinicalTrials.gov/show/NCT02925221 Recruiting Otsuka Canada Pharmaceutical Inc. 2021-12-31
NCT02848521 A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe https://ClinicalTrials.gov/show/NCT02848521 Active, not recruiting Otsuka Pharmaceutical Europe Ltd 2019-10-31
NCT02847624 Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD https://ClinicalTrials.gov/show/NCT02847624 Recruiting Otsuka Pharmaceutical Co., Ltd. 2022-03-31
NCT02739750 Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT02739750 Active, not recruiting Indiana University 2019-10-31
NCT02322385 Clinical Implications of DNA Analysis on ADPKD https://ClinicalTrials.gov/show/NCT02322385 Completed Kyorin University 2016-12-31
NCT02142101 Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02142101 Completed Icahn School of Medicine at Mount Sinai 2015-12-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01430494 Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT01430494 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2014-10-31
NCT01401998 UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource https://ClinicalTrials.gov/show/NCT01401998 Recruiting Children’s National Research Institute 2022-09-30
NCT01348035 Efficacy Study of Water Drinking on PKD Progression. https://ClinicalTrials.gov/show/NCT01348035 Completed Kyorin University 2012-11-30
NCT04344769 Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://ClinicalTrials.gov/show/NCT04344769 Recruiting Mayo Clinic 2020-10-04
NCT04338048 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study https://ClinicalTrials.gov/show/NCT04338048 Recruiting Children’s National Research Institute 2025-10-30
NCT04111692 A Prospective Observational Study of Foam Sclerotherapy . https://ClinicalTrials.gov/show/NCT04111692 Recruiting Mayo Clinic 2020-12-10
NCT04023214 The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT04023214 Completed Sheffield Teaching Hospitals NHS Foundation Trust 2018-12-31
NCT03970018 ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? https://ClinicalTrials.gov/show/NCT03970018 Completed CHU de Reims 2018-07-01
NCT03948113 Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). https://ClinicalTrials.gov/show/NCT03948113 Completed CHU de Reims 2015-12-31
NCT03889392 Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD https://ClinicalTrials.gov/show/NCT03889392 Completed Asan Medical Center 2018-12-31
NCT03726463 Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD https://ClinicalTrials.gov/show/NCT03726463 Recruiting Asan Medical Center 2023-11-30
NCT03717883 ADPKD Alterations in Hepatic Transporter Function https://ClinicalTrials.gov/show/NCT03717883 Completed University of North Carolina, Chapel Hill 2020-01-29
NCT03651388 Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia https://ClinicalTrials.gov/show/NCT03651388 Completed Centre Hospitalier Universitaire Dijon 2012-06-30
NCT03493802 Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD https://ClinicalTrials.gov/show/NCT03493802 Active, not recruiting Mayo Clinic 2020-06-01
NCT01114594 Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT01114594 Completed The Rogosin Institute 2012-04-30
NCT01039987 Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT01039987 Completed University of Pittsburgh 2011-03-31
NCT00873678 Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome https://ClinicalTrials.gov/show/NCT00873678 Completed Assistance Publique - Hôpitaux de Paris 2010-01-31
NCT02250287 New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease https://ClinicalTrials.gov/show/NCT02250287 Completed Mayo Clinic 2016-03-31
NCT00792155 Polycystic Kidney Disease Data Repository https://ClinicalTrials.gov/show/NCT00792155 Recruiting The Rogosin Institute 2026-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02497521 The German ADPKD Tolvaptan Treatment Registry https://ClinicalTrials.gov/show/NCT02497521 Recruiting University of Cologne 2025-11-30
NCT02084849 ADPKD Cohort Study https://ClinicalTrials.gov/show/NCT02084849 Completed Emory University 2015-05-31
NCT01873235 PKD Clinical and Translational Core Study https://ClinicalTrials.gov/show/NCT01873235 Recruiting University of Maryland, Baltimore 2022-06-30
NCT04039061 ADPKD Patient Registry https://ClinicalTrials.gov/show/NCT04039061 Recruiting PKD Foundation 2029-09-04
NCT03901521 Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository https://ClinicalTrials.gov/show/NCT03901521 Recruiting Weill Medical College of Cornell University 2029-12-31
NCT02936791 PKD Biomarkers Study https://ClinicalTrials.gov/show/NCT02936791 Recruiting University of Kansas Medical Center 2020-06-30